Ep 5 - RET-Fusion: 9 Years Beyond a 3% Survival Chance of Stage IV NSCLC

Ep 7 - TROP2 Antibody-Drug Conjugate

This episode covers the basics of TROP2 antibody-drug conjugates (ADCs), a new and promising treatment for lung cancer. We explain how ADCs work differently from chemotherapy and immunotherapy by delivering powerful cancer-killing drugs directly to tumor cells with fewer side effects. The episode highlights TROP2 as a key target in lung cancer and discusses the latest research on TROP2 ADCs, including datopotamab deruxtecan. We review recent clinical trial results showing improved outcomes for some patients, current FDA review status, and what these advances could mean for patients and caregivers. The episode also touches on ongoing research, potential side effects, and the growing excitement and investment in ADC therapies for cancer. See More ⁠HERE⁠ [https://patientsavvy.org/patient-story/]

Ep 6 - MET-Amplification: Achieving Stable Condition in Extensive Metastatic NSCLC

In this episode, we explore the groundbreaking impact of targeted therapy for MET amplification in non-small cell lung cancer (NSCLC), focusing on how it has transformed the treatment landscape for patients with advanced, metastatic disease. We’ll delve into the science behind MET amplification, explaining how targeting its overactive signaling can hinder tumor growth and potentially offer new hope for patients facing stage IV NSCLC.  By the end of this episode, our goal is to equip you with the knowledge to discuss targeted therapies with confidence, empowering you to make informed decisions with your healthcare team regarding the most appropriate treatment options for your individual needs. Cre: Patient Resource See More HERE [https://patientsavvy.org/patient-story/]

Ep 5 - RET-Fusion: 9 Years Beyond a 3% Survival Chance of Stage IV NSCLC

In this episode, we dive into the transformative potential of targeted therapy for RET fusion-positive lung cancer, spotlighting how it has dramatically reshaped outcomes for a young patient with extensive metastatic NSCLC. We’ll break down the science behind the RET pathway, revealing how blocking its abnormal signals can stall tumor growth and even turn stage IV cancer into a more manageable condition. We’ll also address possible side effects, ensuring you gain a balanced perspective on these breakthrough medications. By the end of this episode, our goal is to empower you with the knowledge to discuss RET-targeted therapies more confidently with your healthcare team, helping you weigh their suitability and benefits for your specific situation Source: Cleveland Clinic See More ⁠HERE [⁠https://patientsavvy.org/patient-story/⁠]

Ep 4 - PD-L1 immunotherapy: Unleashing Your Immune System Against Cancer

In this episode, we delve into immunotherapy which offers a unique approach compared to targeted therapy. We'll explore how immunotherapy has dramatically shifted the prognosis for lung cancer patients, especially those with advanced disease Our discussion will break down the science behind the PD-1/PD-L1 pathway, explaining how blocking this interaction can reactivate your immune system to combat cancer and potentially provide long-term benefits. We’ll also address its possible side effects, ensuring you have a balanced perspective on the treatment. By the end of this episode, our goal is to empower you with the knowledge to confidently discuss PD-L1 immunotherapy with your healthcare team, including assessing its suitability and potential benefits for your specific case. Source: L’Hopital d’Ottawa See More HERE [⁠https://patientsavvy.org/patient-story/⁠]

Ep 3 - ALK mutation: Keep cancer remain under control regardless of recurrence

In this episode, we dive into ALK-targeted treatment and its profound impact on the cancer journey of a survivor with extensive metastases. We'll unravel the science behind ALK and illustrate how therapies aimed at this biomarker have revolutionized treatment strategies.  Notably, this approach highlights that targeted therapy remains a viable option even after progression or recurrence following chemotherapy and immunotherapy. Join us as we share an inspiring story of resilience, showcasing both the challenges and breakthroughs that define this remarkable journey. Source: City of hope  https://patientsavvy.org/patient-story/